• Trinity Biotech released new pre-pivotal clinical trial analysis showing its CGM+ wearable can flag overnight false low glucose alarms caused by sensor compression.
• Results have already been presented as newly reported study findings from a trial completed in Q2 2026.
• The data support a differentiated, multi-sensor approach that adds physiological context to reduce disruptive false alerts versus glucose-only CGMs.
• The company plans to incorporate the feature as CGM+ advances toward a pivotal trial and regulatory submission.
• Management framed the capability as a potential differentiator in a global CGM market it estimated at $15 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trinity Biotech plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001554855-26-001482), on July 02, 2026, and is solely responsible for the information contained therein.